Vicarious Surgical CTO sells shares worth over $3,500 By Investing.com

In a recent transaction, the Chief Technology Officer of Vicarious Surgical Inc. (NYSE:RBOT), Sammy Khalifa, sold shares of the company’s stock, generating over $3,500 in proceeds. The transaction took place on August 20, 2024, and was reported in a Form 4 filing with the Securities and Exchange Commission.

Khalifa disposed of 559 shares of Class A Common Stock at a weighted average price ranging from $6.20 to $6.51 per share. The total value of the shares sold amounted to approximately $3,515, based on the average sale price of $6.2895 per share. The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units granted to Khalifa on May 19, 2022.

Following the sale, Khalifa’s ownership in the company stands at 39,001 shares of Vicarious Surgical Inc. The company, which is classified under the orthopedic, prosthetic, and surgical appliances and supplies industry, is incorporated in Delaware with a fiscal year ending on December 31.

Investors and stakeholders can request detailed information about the number of shares sold at each separate price from Khalifa, Vicarious Surgical Inc., or the SEC if needed.

The transaction was signed off by Erin Checka, Attorney-in-Fact, on August 21, 2024. Khalifa’s recent sale is part of the routine financial disclosures required by company insiders and provides transparency into the trading activities of Vicarious Surgical’s executives.

In other recent news, Vicarious Surgical Inc. has experienced several noteworthy developments. The company reported its Q2 financial results, disclosing an adjusted earnings per share (EPS) of -$2.86, slightly below the consensus estimate of -$2.72. Operating expenses increased by 17% year-over-year to $17.7 million, primarily due to investments in research and development and general and administrative expenses. Despite these increased costs, Vicarious Surgical confirmed it is on track with the development of its V1.0 system, projected for completion by Fall 2024.

TD Cowen raised its price target for Vicarious Surgical to $10.00 from $1.50, maintaining a Buy rating on the stock. This adjustment was made in light of the company’s progress in the development of its robotic system. In contrast, Piper Sandler lowered its price target for the company to $12 from $30, while maintaining a neutral stance. This decision followed the announcement of the company’s Q2 results.

Vicarious Surgical is advancing its V1.0 surgical system integration and clinical trial plans, including partnerships with hospital systems like LSU Health New Orleans. These recent developments are part of the company’s broader strategy to transition its technology from development to practical application in surgical procedures. The company anticipates initial clinical patient testing in 2025.

InvestingPro Insights

In light of the recent stock sale by Vicarious Surgical Inc.’s (NYSE:RBOT) Chief Technology Officer, Sammy Khalifa, investors may be interested in the company’s current financial health and market performance. According to InvestingPro data, Vicarious Surgical Inc. has a market capitalization of $38.04 million and is experiencing significant volatility in its stock price, with a 16.88% return over the last week but substantial declines over longer periods, including a 76.83% drop over the past year.

InvestingPro Tips suggest that while the company holds more cash than debt on its balance sheet, which is a positive sign of liquidity, it is quickly burning through cash and has weak gross profit margins. Analysts do not anticipate the company will be profitable this year, and the valuation implies a poor free cash flow yield. These factors could be contributing to the stock’s poor performance over the last month and three months, with price decreases of 19.75% and 40.93%, respectively.

For investors seeking a deeper analysis of Vicarious Surgical Inc., there are additional InvestingPro Tips available at InvestingPro Vicarious Surgical Inc., which offer insights into the company’s financials, market position, and potential future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.